Deutsche Märkte geschlossen

BioDelivery Sciences International, Inc. (BD5.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
2,6600-0,0800 (-2,92%)
Börsenschluss: 3:03PM MEZ

BioDelivery Sciences International, Inc.

4131 ParkLake Avenue
Suite 225
Raleigh, NC 27612
United States
919 582 9050
http://www.bdsi.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter176

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Jeffrey Allen BaileyCEO & Director599,96kN/A1963
Mr. Scott M. PleshaPres & Chief Commercial Officer629,46kN/A1965
Mr. James Vollins J.D.Gen. Counsel, Chief Compliance Officer & Corp. Sec.586,68k45,09k1969
Dr. Thomas B. Smith FAAFP, M.D.Chief Medical Officer570,06kN/A1961
Mr. John GolubieskiCFO & Chief Accounting OfficerN/AN/A1965
Mr. Joseph M. LockhartSr. VP of OperationsN/AN/AN/A
Mr. Kevin OstranderSr. VP of Bus. Devel.N/AN/AN/A
Dr. Bill McCarbergMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardN/AN/AN/A
Dr. Arthur G. Lipman PharmDMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardN/AN/AN/A
Dr. Jeff KatzMember of Scientific Advisory Board and Member of Arius Scientific Advisory BoardN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.

Corporate Governance

BioDelivery Sciences International, Inc.s ISS Governance QualityScore, Stand 26. September 2021, lautet 5. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.